Journal of diabetes and its complications最新文献

{"title":"The NGAL as a prognostic biomarker of kidney injury in children and adolescents with type 1 diabetes mellitus: A systematic review and meta-analysis","authors":"Nikolaos Gkiourtzis ,&nbsp;Anastasia Stoimeni ,&nbsp;Panagiota Michou ,&nbsp;Konstantinos Cheirakis ,&nbsp;Maria Moutafi ,&nbsp;Aristeidis Christakopoulos ,&nbsp;Agni Glava ,&nbsp;Paraskevi Panagopoulou ,&nbsp;Georgios Tsigaras ,&nbsp;Assimina Galli-Tsinopoulou ,&nbsp;Athanasios Christoforidis ,&nbsp;Despoina Tramma","doi":"10.1016/j.jdiacomp.2025.109002","DOIUrl":"10.1016/j.jdiacomp.2025.109002","url":null,"abstract":"<div><h3>Aims</h3><div>A major complication of type 1 diabetes is diabetic kidney disease (DKD). Albuminuria and impaired glomerular filtration rate are the main characteristics of DKD. Neutrophil gelatinase-associated lipocalin (NGAL) levels may rise even in the early stages of DKD, even in patients with normoalbuminuria. We present the first systematic review and meta-analysis examining the prognostic role of NGAL exclusively in pediatric patients with type 1 diabetes.</div></div><div><h3>Methods</h3><div>A search through major databases was carried out until September 24, 2024, investigating the prognostic role of NGAL in kidney injury in pediatric patients with type 1 diabetes. A <em>p</em> &lt; 0.05 was considered statistically significant. A study quality assessment was conducted using the Newcastle-Ottawa Scale.</div></div><div><h3>Results</h3><div>The standardized mean difference in urinary NGAL (uNGAL) levels between the type 1 diabetes group and healthy controls was statistically significant (SMD = 0.63, 95%CI [0.36,0.90]). A moderate positive relationship between uNGAL and ACR was identified (<em>r</em> = 0.53, 95 % CI [0.31–0.70]). The uNGAL revealed a high overall diagnostic accuracy (AUC = 0.881).</div></div><div><h3>Conclusions</h3><div>Urinary NGAL appears to be a valuable biomarker for early detection and understanding of DKD in individuals with type 1 diabetes. Future clinical studies should prioritize assessing the accuracy of NGAL in identifying kidney injury in pediatric patients with type 1 diabetes and the association of NGAL with traditional biomarkers in groups with similar characteristics.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 5","pages":"Article 109002"},"PeriodicalIF":2.9,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143714987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(25)00062-5","DOIUrl":"10.1016/S1056-8727(25)00062-5","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 109009"},"PeriodicalIF":2.9,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urogenital side effects in male subjects with type 2 diabetes treated with SGLT-2 inhibitors: A single centre, longitudinal observation","authors":"Alice Del Zoppo ,&nbsp;Chiara Rovera ,&nbsp;Giovanni Petralli ,&nbsp;Diego Moriconi ,&nbsp;Anna Solini","doi":"10.1016/j.jdiacomp.2025.109015","DOIUrl":"10.1016/j.jdiacomp.2025.109015","url":null,"abstract":"<div><h3>Objective</h3><div>SGLT-2 inhibitors (SGLT-2i) provide good glycaemic control and weight loss, ensuring clinically relevant cardiorenal benefits in subjects with and without type 2 diabetes (T2D); however, their use is related to an enhanced risk of urogenital infections, mainly in female subjects. We performed a prospective observation to assess incidence of urogenital complications in male sex new users of gliflozins.</div></div><div><h3>Subjects and methods</h3><div>In the 2021–2023 years, solely based on clinical indication, we started such therapy in 272 male T2D subjects; follow up visits were performed after about 1 year.</div></div><div><h3>Results</h3><div>At follow up, 90 subjects had discontinued SGLT-2i; 36 of them (40 %) due to onset of urogenital symptoms. We observed 6 cases of phimosis. Subjects who discontinued the treatment due to these side effects had a higher BMI and a better eGFR at baseline and they were less frequently treated with DPP-IV inhibitors.</div></div><div><h3>Conclusions</h3><div>A proper evaluation of the patient's phenotype might be useful in identifying subjects less prone to develop side effects driving SGLT-2i discontinuation; the combined use of SGLT-2i and DPP-IV inhibitors appears to be associated to a better long-term compliance to therapy in men.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 5","pages":"Article 109015"},"PeriodicalIF":2.9,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The burden of depression among patients with type 2 diabetes: An umbrella review of systematic reviews","authors":"Nora Wulandari ,&nbsp;Aly Lamuri ,&nbsp;Fenneke van Hasselt ,&nbsp;Talitha Feenstra ,&nbsp;Katja Taxis","doi":"10.1016/j.jdiacomp.2025.109004","DOIUrl":"10.1016/j.jdiacomp.2025.109004","url":null,"abstract":"<div><h3>Objective</h3><div>Depression is common among patients with type 2 diabetes (T2D) which is a major global health concern. This umbrella review aims to explore differences in reported depression prevalence among people with type 2 diabetes and to identify the factors contributing to the variation.</div></div><div><h3>Methods</h3><div>A literature search was conducted in PubMed, EMBASE, PsycINFO and Cochrane. We included systematic reviews with or without a meta-analysis that investigated the prevalence of depression in adult patients (age 18 years or older) with T2D. Two independent reviewers screened titles and abstracts. The following data were extracted: study characteristics, depression assessment approach, and depression prevalence from systematic reviews and each primary study.</div></div><div><h3>Findings</h3><div>Of the 23 systematic reviews meeting inclusion criteria, comprising 649 unique primary studies, pooled depression prevalence ranged from 8.9 % to 61.6 %, with substantial heterogeneity (<em>I</em>² values ranged from 89.41 % to 99.96 %). Studies conducted in the African (0.11 [95%CI 0.04–0.17]), Eastern Mediterranean (0.19 [95%CI 0.15–0.24]) and South-East Asia (0.08 [95%CI 0.03–0.13]) reported higher prevalence compared to the Americas. Additionally, studies utilizing screenings other than the Hamilton Depression Rating Scale (HDRS) exhibited lower prevalence rates (between −22 % and −0.10 %).</div></div><div><h3>Conclusion</h3><div>The burden of depression was high among people with T2D. Substantial variation was found in the prevalence of depression among individuals with T2D, depending on the WHO region and the depression assessment approach.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 5","pages":"Article 109004"},"PeriodicalIF":2.9,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes to insulin pump settings throughout pregnancy for individuals using assisted hybrid closed-loop therapy versus sensor-augmented pump therapy","authors":"Jocelynn King ,&nbsp;Elizabeth Buschur ,&nbsp;Rachel Garcetti ,&nbsp;Laura Pyle ,&nbsp;Casey Sakamoto ,&nbsp;Janet Snell-Bergeon ,&nbsp;Emily Nease ,&nbsp;Anna Bartholomew ,&nbsp;Kathleen Dungan ,&nbsp;Sarit Polsky","doi":"10.1016/j.jdiacomp.2025.109000","DOIUrl":"10.1016/j.jdiacomp.2025.109000","url":null,"abstract":"<div><h3>Aims</h3><div>We compared changes in insulin pump settings and insulin distribution throughout pregnancy and early postpartum for participants with type 1 diabetes using sensor-augmented pump therapy (SAPT) or hybrid closed-loop (HCL) therapy without a pregnancy-specific glucose target.</div></div><div><h3>Methods</h3><div>In this investigator-initiated trial 23 participants were randomized at 14–18 weeks gestation to HCL therapy or SAPT until 4–6 weeks postpartum. We compared the changes to insulin pump settings and insulin delivery between groups using mixed-effects models.</div></div><div><h3>Results</h3><div>There were no significant differences in total daily insulin dose between HCL and SAPT groups from preconception through 4–6 weeks postpartum. However, the proportion of total insulin coming from bolus insulin was higher for the HCL group in month 9 (70.9 % HCL vs 57.9 % SAPT, p = 0.014). The HCL group had a lower total daily basal dose compared to SAPT in months 9 and 10 (p &lt; 0.05 for both) and a higher total daily bolus dose at month 10 compared to the SAPT group (55.2 units/day vs 37.1 units/day, p = 0.025). The number of changes to pump settings did not differ between groups. Active insulin time was significantly shorter in the HCL group at almost all time points through month 9 of pregnancy and early postpartum. Carbohydrate-to-insulin ratios were stronger for breakfast (p = 0.020) and lunch (p = 0.005) over gestation in the HCL group.</div></div><div><h3>Conclusion</h3><div>More bolus insulin and less basal insulin were used by the HCL group compared to the SAPT group, at least in part due to pump settings that contribute to more bolus insulin delivery.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 109000"},"PeriodicalIF":2.9,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of the therapeutic effects of pregabalin, gabapentin, and duloxetine in diabetic peripheral neuropathy: A retrospective study","authors":"Jiyong Ahn ,&nbsp;Reza Shahriarirad ,&nbsp;Kyeongeon Kwon ,&nbsp;Lorena Bejarano-Pineda ,&nbsp;Gregory Waryasz ,&nbsp;Soheil Ashkani-Esfahani","doi":"10.1016/j.jdiacomp.2025.109001","DOIUrl":"10.1016/j.jdiacomp.2025.109001","url":null,"abstract":"<div><h3>Introduction</h3><div>This study aimed to compare the effects of pregabalin, gabapentin, and duloxetine on diabetic peripheral neuropathy (DPN) to guide tailored treatment.</div></div><div><h3>Materials and methods</h3><div>In this retrospective study, 180 patients with type 2 diabetes and DPN were matched 1:1:1 across three groups based on HbA1c and age, resulting in 60 patients per group. Clinical data were collected, and the painDETECT score was used to evaluate treatment response over six weeks.</div></div><div><h3>Results</h3><div>After six weeks, the gabapentin group had significantly higher pain scores than the pregabalin (P = 0.002) and duloxetine groups (P &lt; 0.001). The pregabalin group's scores were higher than the duloxetine group's, but not significantly (P = 0.62). Side effects were more frequent with duloxetine (23.3 %) compared to gabapentin (1.7 %) and pregabalin (6.7 %) (P = 0.001). Among those with over 50 % improvement, mean HbA1c levels were 9.42 for gabapentin, 10.43 for pregabalin, and 7.72 for duloxetine. Duloxetine significantly lowered HbA1c compared to gabapentin (P = 0.001) and pregabalin (P = 0.001), with no significant difference between gabapentin and pregabalin (P = 0.45).</div></div><div><h3>Conclusion</h3><div>Duloxetine and pregabalin effectively treat DPN. Gabapentin and pregabalin are suitable for patients with HbA1c over 8.7, while duloxetine is better for those with well-controlled HbA1c. Treatment should consider side effects, adherence, costs, and response time.</div></div><div><h3>Level of the evidence</h3><div>Level III retrospective cohort study.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 109001"},"PeriodicalIF":2.9,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143619500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of non-surgical treatment in diabetes-associated periodontitis on immune/inflammatory and oxidative stress biomarkers: A pilot study","authors":"Steffany Bernardo Oliveira ,&nbsp;Ana Luíza Pereira Assunção Silveira ,&nbsp;Yeon Jung Kim ,&nbsp;Jônatas Bussador do Amaral ,&nbsp;André Luis Lacerda Bachi ,&nbsp;Margareth Afonso Torres ,&nbsp;Karen Melissa Gonçalves Oliveira ,&nbsp;Daniela Alves de Abreu ,&nbsp;Leonardo Diniz Resende ,&nbsp;Débora Pallos ,&nbsp;Carolina Nunes França","doi":"10.1016/j.jdiacomp.2025.108999","DOIUrl":"10.1016/j.jdiacomp.2025.108999","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the effects of non-surgical periodontal treatment on the levels of cytokines, sIgA, antimicrobial peptides, oxidative and antioxidative agents in comparison between patients with and without diabetes.</div></div><div><h3>Methods</h3><div>A case-control study that included patients (n = 45) with periodontitis who have or do not have diabetes. Cytokine concentrations in crevicular gingival fluid (GCF) and saliva were determined using LUMINEX and ELISA assays, respectively. Salivary levels of lysozyme, cathelicidin (LL-37), total antioxidant capacity (TAC) and total peroxide were determined colorimetrically before (T0) and one month after completion of periodontitis treatment (T1).</div></div><div><h3>Results</h3><div>There were no significant differences in the concentrations of cytokines in GCF between the groups and T0 and T1. Salivary concentrations of lysozyme and IL-10 were significantly reduced in T1 compared to T0 in the diabetes group (p = 0.0260 and p = 0.0034, respectively), whilst TNF-α concentration was higher in T1 (p = 0.0443). The salivary concentrations of TNF-α observed in the non-diabetes group at T1 decreased at T0 (p = 0.0313). The salivary concentration of TNF-α was increased in the diabetes group compared to the non-diabetes group at T1 (p = 0.0008).</div></div><div><h3>Conclusions</h3><div>An improvement in salivary inflammatory status was observed in the group without diabetes, which was not found in the group with diabetes after non-surgical periodontal treatment.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108999"},"PeriodicalIF":2.9,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of the stress hyperglycemia ratio for all-cause mortality in stroke patients with diabetes or prediabetes","authors":"Meng Jin ,&nbsp;Ziyi Bao ,&nbsp;Xiaqing Hong ,&nbsp;Songbin He ,&nbsp;Feng Gao","doi":"10.1016/j.jdiacomp.2025.108979","DOIUrl":"10.1016/j.jdiacomp.2025.108979","url":null,"abstract":"<div><h3>Background</h3><div>The stress hyperglycemia ratio (SHR), originally proposed in 2015 by Robert et al., is more significantly relevant and predictive of critical illness than absolute hyperglycemia. Several studies have validated the association between stress hyperglycemia ratio and cerebrovascular disease. However, the value of stress hyperglycemia ratio for severe stroke patients admitted to the ICU remains uncertain. The aim of this study was to investigate the relationship between stress hyperglycemia ratio and clinical short- and long-term prognosis of critically ill patients with acute ischemic stroke (AIS).</div></div><div><h3>Methods</h3><div>Clinical data from 893 critically ill patients with ischemic stroke (IS) were extracted from the Medical Information Marketplace for Intensive Care (MIMIC-IV) database and 793 critically ill IS patients with 1 year of follow-up. The SHR is expressed by the formula: SHR = [(admission glucose (mg/dl)) / (28.7 × HbA1c (%) − 46.7)]. The study population was categorized into quartiles based on SHR level. Outcomes included ICU mortality, hospital mortality, and 1-year mortality. Cox proportional risk regression analysis and restricted cubic spline curves were used to elucidate the association between SHR and clinical prognosis in critically ill patients with AIS.</div></div><div><h3>Results</h3><div>There were 69 ICU deaths and 100 in-hospital deaths in cohort 1, and 229 patients experienced all-cause mortality during the 1-year follow-up in cohort 2. Multivariate Cox proportional risk analysis showed that elevated SHR was significantly associated with an increased risk of hospital and 1-year all-cause mortality. After adjusting for confounders, patients with elevated SHR were significantly associated with hospital mortality (adjusted risk ratio, 1.870; 95 % confidence interval, 1.180–2.962; <em>P</em> = 0.008) and 1-year mortality (adjusted risk ratio, 2.325; 95 % confidence, 1.729–3.127; <em>P</em> &lt; 0.001). Restricted cubic spline bars showed that a progressively increasing risk of all-cause mortality was associated with an elevated SHR.</div></div><div><h3>Conclusion</h3><div>Stress hyperglycemia ratios were significantly associated with in-hospital and 1-year all-cause mortality in critically ill IS patients. Moreover, we found that non-diabetic and prediabetic patients showed an increased risk of all-cause mortality. It is suggested that SHR may be useful in identifying ischemic stroke patients at high risk of all-cause mortality and providing personalized interventions as early as possible.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108979"},"PeriodicalIF":2.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating social determinants of health into global approaches to early-onset type 2 diabetes","authors":"J. Eleanor Seo ,&nbsp;Manfredi Rizzo ,&nbsp;Tiffany M. Powell-Wiley","doi":"10.1016/j.jdiacomp.2025.108982","DOIUrl":"10.1016/j.jdiacomp.2025.108982","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108982"},"PeriodicalIF":2.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of efficacy and safety of pioglitazone and SGLT2 inhibitors in treating Asian patients in MASLD associated with type 2 diabetes: A meta-analysis","authors":"Lingyan Liu ,&nbsp;Yongkun Deng ,&nbsp;Lijuan Yang ,&nbsp;Miaojiao Wang ,&nbsp;Yong Lai","doi":"10.1016/j.jdiacomp.2025.108998","DOIUrl":"10.1016/j.jdiacomp.2025.108998","url":null,"abstract":"<div><h3>Objective</h3><div>To comprehensively evaluate the therapeutic efficacy of pioglitazone and SGLT2 inhibitors (SGLT2i) in patients with MASLD and Type 2 Diabetes(T2DM).</div></div><div><h3>Methods</h3><div>Electronic databases, including Web of Science, PubMed, the Cochrane Library, China National Knowledge Internet (CNKI), Wan-Fang Digital Database, and China Science and Technology Journal Database (VIP) were searched from inception to December 2024. Two reviewers independently assessed study eligibility, performed continuous data extraction， and independently evaluated bias risks. Liver ultrasonography, computed tomography (CT), and biochemical indices were utilized to determine the impact of treatment in both groups. Improvement in liver biomarkers and fibrosis as primary outcome indicators; Improvement in body composition, metabolic parameters, glucose parameters, and incidence of adverse effects as a secondary outcome indicator. For continuous variables, mean and standard deviation (SD) were extracted. RevMan 5.4 software was used to systematically analyze the literature, including heterogeneity testing, odds ratios (OR) calculation, and 95 % confidence intervals (CI) for each influencing factor.</div></div><div><h3>Results</h3><div>Nine randomly controlled trials with 755 Asian participants were included. Our research showed that SGLT2i was more effective than pioglitazone in improving fibrosis-4 score (SMD 0.41 [95%CI 0.18,0.64] <em>p</em> = 0.005), visceral fat area (SMD 0.34 [95%CI 0.14,0.54] <em>p</em> = 0.0007), BMI (SMD 0.29 [95%CI 0.03,0.56] <em>p</em> = 0.03), and low-density lipoprotein levels (SMD 0.21 [95%CI 0.04,0.38] <em>p</em> = 0.01). In contrast, no statistically significant differences were observed in other outcomes.</div></div><div><h3>Conclusions</h3><div>Our study demonstrated that in patients with MASLD and T2DM, SGLT2i was more effective overall in improving liver fibrosis, blood lipids, liver fat, and body composition in the short term. These findings establish a theoretical basis for safe and rational drug use in clinical practice. Additionally, they may contribute to new insights into the pathogenesis of MASLD and type 2 diabetes and drug discovery and development efforts.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108998"},"PeriodicalIF":2.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}